KEGG   DRUG: D06193Help
Entry
D06193                      Drug                                   

Name
Toralizumab (USAN/INN)
Activity
Treatment of antibody-mediated disorders [immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis], T-cell-mediated diseases [multiple sclerosis, Crohn's disease, and transplantation such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation], and B-cell malignancies [such as CLL/small lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma;
relapsed/refractory Hodgkin's disease] [monoclonal antibody]
Target
CD154 (CD40L) [HSA:959] [KO:K03161]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04514  Cell adhesion molecules (CAMs)
hsa04660  T cell receptor signaling pathway  
 
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines
  TNF family
   CD40L (CD154) [HSA:959] [KO:K03161]
    Toralizumab
     D06193  Toralizumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
252662-47-8
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system